HANGZHOU, China, June 30, 2018 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (“Jo-Jo Drugstores” or the “Company”), a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2018.
Mr. Lei Liu, Chief Executive Officer and Chairman of Jo-Jo Drugstores, Inc., commented, “Fiscal year 2018 has been an important transition year for China Jo-Jo Drugstores with revenues increased by 17.9% year-over-year to $96.11 million. We expanded our retail business, opening 55 new retail drugstores in key locations, and continued to improve services in our existing stores. While our e-commerce business continued its transition following the suspension of OTC drug sales on e-commerce platforms in fiscal year 2017, in the third and fourth quarters of fiscal 2018, our online pharmacy results began to stabilize as we optimized our product range.”
Mr. Liu continued, “We expect our efforts to focus on product selection and price negotiation with suppliers to increase our sales profit margin. Our e-commerce segment will continue its evolution following our initiatives to cooperate with commercial insurance companies, such as the People’s Insurance Company of China, and other active strategies. We look forward to executing our business objectives and we believe that there is still plenty of room for us to continue to grow at a rapid rate in the foreseeable future.”
Fiscal Year 2018 Financial Highlights
|
For the Fiscal Year Ended March 31, |
||||||
|
($ millions, except per share data) |
2018 |
2017 |
Change |
|||
|
Revenues |
96.11 |
81.50 |
17.9% |
|||
|
Retail drugstores |
61.98 |
51.79 |
19.7% |
|||
|
Online pharmacy |
12.13 |
15.39 |
(21.2%) |
|||
|
Wholesale |
22.00 |
14.32 |
53.6% |
|||
|
Gross profit |
20.13 |
16.63 |
21.0% |
|||
|
Gross margin |
20.9% |
20.4% |
0.5 pp* |
|||
|
Loss from operations |
(18.02) |
(6.10) |
195.5% |
|||
|
Net loss attributable to Jo-Jo Drugstores |
(17.06) |
(5.64) |
202.3% |
|||
|
Loss per share |
(0.68) |
(0.28) |
141.4% |
|||
|
*Notes: pp represents percentage points |
||||||
- Revenues increased by 17.9% to $96.11 million for the fiscal year ended March 31, 2018 from $81.50 million for the last fiscal year, mainly due to the increase in retail drugstores and wholesale business, partially offset by the decrease in online pharmacy business.
- Gross profit increased by 21.0% to $20.13 million for the fiscal year ended March 31, 2018 from $16.63 million for the last fiscal year. Gross margin increased by 0.5 percentage points to 20.9% from 20.4% for the last fiscal year.
Fiscal Year ended March 31, 2018 Financial Results
Revenue
Revenue for the fiscal year ended March 31, 2018 increased by $14.61 million, or 17.9%, to $96.11 million from $81.50 million for the last fiscal year. The increase in revenue was primarily due to the increase in retail drugstores and wholesale business, partially offset by the decrease in online pharmacy business.
|
For the Fiscal Year Ended March 31, |
|||||||||||||
|
2018 |
2017 |
||||||||||||
|
($ millions) |
Revenues |
Cost of |
Gross |
Revenues |
Cost of |
Gross |
|||||||
|
Retail drugstores |
61.98 |
45.92 |
25.9% |
51.79 |
38.09 |
26.5% |
|||||||
|
Online pharmacy |
12.13 |
10.86 |
10.5% |
15.39 |
13.83 |
10.1% |
|||||||
|
Wholesale |
22.00 |
19.21 |
12.7% |
14.32 |
12.95 |
9.6% |
|||||||
|
Total |
96.11 |
75.99 |
20.9% |
81.50 |
64.87 |
20.4% |
|||||||
Revenue from the retail drugstores segment increased by $10.19 million, or 19.7%, to $61.98 million for the fiscal year ended March 31, 2018 from $51.79 million for the last fiscal year. The increase was primarily due to the increased number of stores, close monitoring of health products suitable to communities, brand-name health product sales campaign in cooperation with brand name suppliers, and value-added customer services such as chronic disease monitoring.
Revenue from the online pharmacy segment decreased by $3.26 million, or 21.2%, to $12.13 million for the fiscal year ended March 31, 2018 from $15.39 million for the last fiscal year. The decrease was mainly caused by a decline in our sales via e-commerce platforms. The decline in sales was due to the suspension of OTC drug sales on e-commerce platforms in the second quarter of fiscal year 2017 by the CFDA. The Company is adding more non-medical health products such as nutritional supplements into our sales menu to counteract the decline in sales of OTC drug category via e-commerce platforms.
Revenue from the wholesale segment increased by $7.68 million, or 53.6%, to $22.00 million for the fiscal year ended March 31, 2018 from $14.32 million for the last fiscal year. The increase was primarily a result of the Company’s ability to resell certain products, which our retail stores made large orders on, to other vendors at competitive prices.
Gross profit and gross margin
Total cost of goods sold increased by $11.12 million, or 17.1%, to $75.99 million for the fiscal year ended March 31, 2018 from $64.87 million for the last fiscal year. Gross profit increased by $3.50 million, or 21.0%, to $20.13 million for the fiscal year ended March 31, 2018 from $16.63 million for the last fiscal year. Overall gross margin increased by 0.5 percentage points to 20.9% for the fiscal year ended March 31, 2018, compared to 20.4% for the last fiscal year.
Gross margins for retail drugstores, online pharmacy and wholesale were 25.9%, 10.5%, and 12.7%, respectively, for the fiscal year ended March 31, 2018. This compared to gross margins for retail drugstores, online pharmacy and wholesale of 26.5%, 10.1%, and 9.6%, respectively, for the last fiscal year.
Loss from operations
Sales and marketing expenses increased by $5.82 million, or 45.0%, to $18.74 million for the fiscal year ended March 31, 2018 from $12.92 million for the last fiscal year, primarily due to increase in labor and rent related to our store expansions and rising local living cost.
General and administrative expenses increased by $10.14 million, or 131.9%, to $17.82 million for the fiscal year ended March 31, 2018 from $7.68 million for the last fiscal year. The increase in general and administrative expenses was primarily due to the increased number of administrative staff and their compensation, as well as additional accounts receivable and advances to vendors allowance of $4.7 million in the fiscal year ended March 31, 2018 as compared to an increase of $0.7 million in allowance in the year ended March 31, 2017.
Impairment of long-lived assets was $1.58 million for the fiscal year ended March 31, 2018, compared to $2.12 million for the last fiscal year. Jiuxin Medicine started outsourcing its logistics service to Astro Boy Cloud Pan (Hangzhou) Storage and Logistics Co. Ltd, Jiuxin Medicine’s warehouse lease has been terminated. As a result, approximately unamortized $1,583,186 warehouse improvement is recognized as expense in the year ended March 31, 2018. Such impairment was made after we estimated that the implied fair value of long-lived assets was lower than the carrying value.
Loss from operations increased by $11.92 million, or 195.5%, to $18.02 million for the fiscal year ended March 31, 2018 from $6.10 million for the last fiscal year. Operating margin was negative 18.8% for the fiscal year ended March 31, 2018, compared to negative 7.5% for the last fiscal year.
Net loss
Net loss attributable to common shareholders for the fiscal year ended March 31, 2018 was $17.06 million, or $0.68 per basic and diluted share. This compared to net loss attributable to common shareholders of $5.64 million, $0.28 per basic and diluted share, for the last fiscal year.
Financial Condition
As of March 31, 2018, the Company had cash of $15.13 million, compared to $18.36 million as of March 31, 2017. Net cash used in operating activities was $2.07 million for the fiscal year ended March 31, 2018, compared to net cash provided by operating cash flow of $1.56 million for the last fiscal year. Net cash used in investing activities was $2.98 million for the fiscal year ended March 31, 2018, compared to $0.05 million for the last fiscal year. Net cash used in financing activities was $0.77 million for the fiscal year ended March 31, 2018, compared to net cash provided by financing activities of $10.64 million for the last fiscal year.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products in China. Jo-Jo Drugstores currently operates retail drugstores and an online pharmacy. It is also a wholesale distributor of products similar to those carried in its pharmacies and it cultivates and sells herbs used for traditional Chinese medicine. For more information about the Company, please visit http://www.chinajojodrugstores.com/. The Company routinely posts important information on its website.
Forward-Looking Statements
This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company’s encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Company Contact:
Frank Zhao
Chief Financial Officer
+86-571-88077108
frank.zhao@jojodrugstores.com
Steve Liu
Investor Relations Director
steve.liu@jojodrugstores.com
Investor Relations Contact:
Tina Xiao
Ascent Investor Relations LLC
+1-917-609-0333
tina.xiao@ascent-ir.com
|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES |
||||||||
|
CONSOLIDATED BALANCE SHEETS |
||||||||
|
March 31, |
March 31, |
|||||||
|
2018 |
2017 |
|||||||
|
ASSETS |
||||||||
|
CURRENT ASSETS |
||||||||
|
Cash |
$ |
15,132,640 |
$ |
18,364,424 |
||||
|
Restricted cash |
16,319,551 |
9,431,386 |
||||||
|
Financial assets available for sale |
175,140 |
87,068 |
||||||
|
Notes receivable |
279,082 |
253,394 |
||||||
|
Trade accounts receivable, net of allowance for doubtful accounts of $4,561,314 and |
8,322,393 |
8,561,596 |
||||||
|
Inventories |
13,429,568 |
9,923,101 |
||||||
|
Other receivables, net of allowance for doubtful accounts of $ 184,720 and $26,854, |
3,098,079 |
2,269,193 |
||||||
|
Advances to suppliers, net of allowance for doubtful accounts of $3,058,092 and |
3,447,452 |
5,504,141 |
||||||
|
Other current assets |
2,116,237 |
1,566,155 |
||||||
|
Total current assets |
62,320,142 |
55,960,458 |
||||||
|
PROPERTY AND EQUIPMENT, net |
2,843,640 |
4,263,157 |
||||||
|
OTHER ASSETS |
||||||||
|
Long-term investment |
40,890 |
46,152 |
||||||
|
Farmland assets |
796,286 |
718,787 |
||||||
|
Long term deposits |
2,501,968 |
2,294,848 |
||||||
|
Other noncurrent assets |
1,253,352 |
1,177,005 |
||||||
|
Intangible assets, net |
4,056,414 |
2,712,611 |
||||||
|
Total other assets |
8,648,910 |
6,949,403 |
||||||
|
Total assets |
$ |
73,812,692 |
$ |
67,173,018 |
||||
|
LIABILITIES AND STOCK HOLDERS’ EQUITY |
||||||||
|
CURRENT LIABILITIES |
||||||||
|
Short-term loan payable |
$ |
– |
$ |
– |
||||
|
Accounts payable, trade |
25,259,526 |
19,441,195 |
||||||
|
Notes payable |
19,180,200 |
12,691,575 |
||||||
|
Other payables |
4,272,523 |
2,916,283 |
||||||
|
Other payables – related parties |
850,342 |
927,052 |
||||||
|
Customer deposits |
4,040,867 |
2,675,030 |
||||||
|
Taxes payable |
366,040 |
681,939 |
||||||
|
Accrued liabilities |
841,993 |
679,350 |
||||||
|
Total current liabilities |
54,811,491 |
40,012,424 |
||||||
|
Purchase option and warrants liability |
138,796 |
496,217 |
||||||
|
Total liabilities |
54,950,287 |
40,508,641 |
||||||
|
COMMITMENTS AND CONTINGENCIES |
||||||||
|
STOCKHOLDERS’ EQUITY |
||||||||
|
Common stock; $0.001 par value; 250,000,000 shares authorized; 28,936,778 and |
28,937 |
25,215 |
||||||
|
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and |
– |
– |
||||||
|
Additional paid-in capital |
43,599,089 |
36,581,248 |
||||||
|
Statutory reserves |
1,309,109 |
1,309,109 |
||||||
|
Accumulated deficit |
(29,661,190) |
(12,601,257) |
||||||
|
Accumulated other comprehensive income |
3,586,460 |
1,350,062 |
||||||
|
Total stockholders’ equity |
18,862,405 |
26,664,377 |
||||||
|
Total liabilities and stockholders’ equity |
$ |
73,812,692 |
$ |
67,173,018 |
||||
|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES |
||||||||
|
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS |
||||||||
|
For the years ended |
||||||||
|
2018 |
2017 |
|||||||
|
REVENUES, NET |
$ |
96,112,706 |
$ |
81,499,045 |
||||
|
COST OF GOODS SOLD |
75,987,537 |
64,872,127 |
||||||
|
GROSS PROFIT |
20,125,169 |
16,626,918 |
||||||
|
SELLING EXPENSES |
18,739,492 |
12,923,192 |
||||||
|
GENERAL AND ADMINISTRATIVE EXPENSES |
17,823,661 |
7,684,862 |
||||||
|
IMPAIRMENT OF LONG-LIVED ASSETS |
1,583,186 |
2,117,042 |
||||||
|
TOTAL OPERATING EXPENSES |
38,146,339 |
22,725,096 |
||||||
|
LOSS FROM OPERATIONS |
(18,021,170) |
(6,098,178) |
||||||
|
INTEREST INCOME |
478,976 |
379,790 |
||||||
|
INTEREST EXPENSE |
– |
(1,349) |
||||||
|
OTHER INCOME, NET |
201,096 |
19,888 |
||||||
|
CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS |
357,421 |
140,032 |
||||||
|
LOSS BEFORE INCOME TAXES |
(16,983,677) |
(5,559,817) |
||||||
|
PROVISION FOR INCOME TAXES |
76,256 |
84,387 |
||||||
|
NET LOSS |
(17,059,933) |
(5,644,204) |
||||||
|
OTHER COMPREHENSIVE LOSS |
||||||||
|
Foreign currency translation adjustments |
2,236,398 |
(1,507,751) |
||||||
|
COMPREHENSIVE LOSS |
(14,823,535) |
(7,151,955) |
||||||
|
WEIGHTED AVERAGE NUMBER OF SHARES: |
||||||||
|
Basic |
25,241,748 |
20,396,217 |
||||||
|
Diluted |
25,241,748 |
20,396,217 |
||||||
|
LOSS PER SHARES: |
||||||||
|
Basic |
$ |
(0.68) |
$ |
(0.28) |
||||
|
Diluted |
$ |
(0.68) |
$ |
(0.28) |
||||
|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES |
||||||||||||||||||||||||||||||||
|
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY |
||||||||||||||||||||||||||||||||
|
Accumulated |
||||||||||||||||||||||||||||||||
|
Common Stock |
Retained Earnings |
other |
Non- |
|||||||||||||||||||||||||||||
|
Number of |
Paid-in |
Statutory |
comprehensive |
controlling |
||||||||||||||||||||||||||||
|
shares |
Amount |
capital |
reserves |
Unrestricted |
income/(loss) |
interest |
Total |
|||||||||||||||||||||||||
|
BALANCE, |
17,735,504 |
$ |
17,736 |
22,088,267 |
1,309,109 |
(6,957,053) |
2,857,813 |
– |
$ |
19,315,872 |
||||||||||||||||||||||
|
Stock based |
1,690,174 |
1,690 |
2,246,960 |
– |
– |
– |
– |
2,248,650 |
||||||||||||||||||||||||
|
Net loss |
– |
– |
– |
– |
(5,644,204) |
– |
– |
(5,644,204) |
||||||||||||||||||||||||
|
Private direct |
4,840,000 |
4,840 |
10,643,160 |
– |
– |
– |
– |
10,648,000 |
||||||||||||||||||||||||
|
Issuance of |
949,000 |
949 |
1,602,821 |
– |
– |
1,603,810 |
||||||||||||||||||||||||||
|
Foreign |
– |
– |
– |
– |
– |
(1,507,751) |
(1,507,751) |
|||||||||||||||||||||||||
|
BALANCE, |
25,214,678 |
$ |
25,215 |
36,581,248 |
1,309,109 |
(12,601,257) |
1,350,062 |
– |
$ |
26,664,377 |
||||||||||||||||||||||
|
Stock based |
3,722,100 |
3,722 |
7,017,841 |
– |
– |
– |
7,021,563 |
|||||||||||||||||||||||||
|
Net loss |
– |
– |
(17,059,933) |
– |
– |
(17,059,933) |
||||||||||||||||||||||||||
|
Foreign |
– |
– |
– |
– |
2,236,398 |
– |
2,236,398 |
|||||||||||||||||||||||||
|
BALANCE, |
28,936,778 |
28,937 |
43,599,089 |
1,309,109 |
(29,661,190) |
3,586,460 |
– |
18,862,405 |
||||||||||||||||||||||||
|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES |
||||||||
|
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||
|
For the years ended |
||||||||
|
2018 |
2017 |
|||||||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
|
Net income |
$ |
(17,059,933) |
$ |
(5,644,204) |
||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Bad debt direct write-off and provision |
4,009,636 |
679,271 |
||||||
|
Depreciation and amortization |
1,383,810 |
1,316,747 |
||||||
|
Impairment of prepayment of lease use right |
– |
1,246,788 |
||||||
|
Farmland assets impairment |
– |
761,403 |
||||||
|
Impairment of land and road improvement |
– |
108,851 |
||||||
|
Impairment of leasehold improvement |
1,583,186 |
– |
||||||
|
Stock based compensation |
7,021,563 |
2,248,650 |
||||||
|
Change in fair value of purchase option derivative liability |
(357,421) |
(140,084) |
||||||
|
Change in operating assets: |
||||||||
|
Accounts receivable, trade |
(2,072,486) |
(717,386) |
||||||
|
Notes receivable |
(1,005) |
(244,713) |
||||||
|
Inventories and biological assets |
(2,411,209) |
191,564 |
||||||
|
Other receivables |
(489,334) |
(773,359) |
||||||
|
Advances to suppliers |
1,121,006 |
(3,020,156) |
||||||
|
Long term deposit |
15,103 |
– |
||||||
|
Other current assets |
(377,391) |
(148,983) |
||||||
|
Other noncurrent assets |
36,091 |
35,509 |
||||||
|
Change in operating liabilities: |
||||||||
|
Accounts payable, trade |
3,726,625 |
3,936,178 |
||||||
|
Other payables and accrued liabilities |
1,115,267 |
1,250,755 |
||||||
|
Customer deposits |
1,048,939 |
237,891 |
||||||
|
Taxes payable |
(362,513) |
234,780 |
||||||
|
Net cash provided by operating activities |
(2,070,066) |
1,559,502 |
||||||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
|
Disposal of financial assets available for sale |
– |
445,968 |
||||||
|
Purchase of financial assets available for sale |
(75,513) |
(89,194) |
||||||
|
Acquisition of equipment |
(414,398) |
(140,209) |
||||||
|
Increase intangible assets |
(1,140,102) |
– |
||||||
|
Termination of a joint venture |
– |
104,059 |
||||||
|
Investment in a joint venture |
– |
(96,180) |
||||||
|
Additions to leasehold improvements |
(1,347,489) |
(270,990) |
||||||
|
Net cash provided by (used in) investing activities |
(2,977,502) |
(46,546) |
||||||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
|
Repayment of short-term bank loan |
– |
(29,731) |
||||||
|
Change in restricted cash |
(5,664,224) |
3,519,030 |
||||||
|
Proceeds from notes payable |
27,461,423 |
24,577,096 |
||||||
|
Repayment of notes payable |
(22,476,740) |
(28,445,215) |
||||||
|
Changes in other payables-related parties |
– |
375,659 |
||||||
|
Proceeds from sale of stock and warrants |
– |
10,648,000 |
||||||
|
Repayment of other payables-related parties |
(91,395) |
– |
||||||
|
Net cash provided by (used in) financing activities |
(770,936) |
10,644,839 |
||||||
|
EFFECT OF EXCHANGE RATE ON CASH |
2,586,720 |
(465,244) |
||||||
|
(DECREASE) INCREASE IN CASH |
(3,231,784) |
11,692,551 |
||||||
|
CASH, beginning of year |
18,364,424 |
6,671,873 |
||||||
|
CASH, end of year |
$ |
15,132,640 |
$ |
18,364,424 |
||||
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
||||||||
|
Cash paid for interest |
$ |
– |
$ |
1,349 |
||||
|
Cash paid for income taxes |
$ |
27,825 |
$ |
57,247 |
||||
|
Issuance of common stocks in exchange of debts |
$ |
– |
$ |
1,603,810 |
||||
Source: China Jo-Jo Drugstores, Inc.
